F S&P 500
5,353.25 -18.00 (-0.34%) F Dow Jones
38,749.00 -180.00 (-0.46%) F Nasdaq
19,045.50 -64.25 (-0.34%) E-mini Russell 2000 Index Futur
2,020.70 -15.20 (-0.75%) Petróleo
77.62 -0.12 (-0.15%) Oro
2,323.20 -3.80 (-0.16%)
PsyBio Therapeutics Corp. (PSYBF)
PsyBio Therapeutics Corp.
1624 Washington Street
Denver, CO 80203
United States
513 449 9585
https://www.psybiolife.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo:
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Mr. Evan Mike Levine | Co-Founder, CEO & Chairman | 321k | N/D | 1966 |
| Mr. Noah Isidore Davis | CFO, Secretary & Director | 239.5k | N/D | 1983 |
| Dr. Michael Spigarelli M.B.A., M.B.E., M.D., Ph.D. | Chief Scientific Officer & Chief Medical Officer | 292.5k | N/D | 1966 |
| Mr. Ross Carmel | Chief Legal Officer & Director | 131.67k | N/D | 1982 |
| Mr. Andrew Jones | Inventor & Chairman of Scientific Advisory Board | N/D | N/D | N/D |
Descripción
PsyBio Therapeutics Corp., a biotechnology company, engages in the research, development, and commercialization of psychedelic-inspired regulated medicines for the treatment of mental health and other disorders in the United States. PsyBio Therapeutics Corp. was formerly known as Leo Acquisitions Corp. and changed its name to PsyBio Therapeutics Corp. in January 2021. The company is headquartered in Denver, Colorado.
Gestión corporativa
La calificación ISS Governance QuickScore de PsyBio Therapeutics Corp. a partir del N/D es N/D. Las puntuaciones principales son Auditoría: N/D; Junta: N/D; Derechos del accionista: N/D; Compensación: N/D.
